Top

Published in:

01-10-2013 | Original Article

A multicenter phase II study of belotecan, a new camptothecin analogue, in elderly patients with previously untreated, extensive-stage small cell lung cancer

Authors: Chang Dong Yeo, Sang Haak Lee, Ju Sang Kim, Seung Joon Kim, Seok Chan Kim, Young Kyoon Kim, Hyeon Hui Kang, Hyung Kyu Yoon, Jeong Sup Song, Hwa Sik Moon, Jin Woo Kim, Kwan Hyoung Kim, Byoung Yong Shim, Chi Hong Kim

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2013

Abstract

Purpose

Belotecan is a new camptothecin analogue and a potent topoisomerase I inhibitor. The aim of this phase II study was to investigate the efficacy and toxicity of belotecan in previously untreated elderly patients with small cell lung cancer (SCLC).

Methods

A total of 26 patients, aged ≥65 years, with previously untreated, extensive-stage SCLC were enrolled in the study. Belotecan was administered by daily intravenous infusion at 0.5 mg/m²/day for 5 consecutive days every 3 weeks.

Results

The overall response rate and disease control rate of chemotherapy on an intention-to-treat basis were 35 and 54 %, respectively. The median overall survival was 6.4 months, and the median time to progression was 2.8 months. The most common toxicity was hematologic. Grade 3 or 4 neutropenia occurred in 80.8 % of patients, and grade 3 or 4 thrombocytopenia in 15.3 %. Non-hematologic toxic effects of grade 3 or 4 were uncommon.

Conclusion

Belotecan had modest efficacy and well-tolerated toxicity in previously untreated, elderly SCLC patients. Single belotecan could be a promising treatment option, considering its lower toxicity in elderly patients who are unsuitable candidates for platinum plus etoposide chemotherapy.

Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan T, Koczywas M, Loo BW Jr, Merritt RE, Moran CA, Niell HB, O’Malley J, Patel JD, Ready N, Rudin CM, Williams CC Jr, Gregory K, Hughes M (2013) Small cell lung cancer. JNCCN 11(1):78–98PubMed

Owonikoko TK, Ramalingam S (2008) Small cell lung cancer in elderly patients: a review. JNCCN 6(3):333–344PubMed

Zochbauer-Muller S, Pirker R, Huber H (1999) Treatment of small cell lung cancer patients. Ann Oncol 10(Suppl 6):83–91PubMedCrossRef

Johnson DH (1993) Treatment of the elderly patient with small-cell lung cancer. Chest 103(1 Suppl):72S–74SPubMed

Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL, Whitehead M, Spaans JN, Graham BC, Goss GD, National Cancer Institute of Canada Clinical Trials G (2008) Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol 26(1):54–59. doi:10.1200/JCO.2007.12.8322 PubMedCrossRef

Hurria A, Kris MG (2003) Management of lung cancer in older adults. CA Cancer J Clin 53(6):325–341PubMedCrossRef

Crul M (2003) CKD-602. Chong Kun Dang. Curr Opin Investig Drugs 4(12):1455–1459PubMed

Kim SJ, Kim JS, Kim SC, Kim YK, Kim YK, Kang JY, Yoon HK, Song JS, Lee SH, Moon HS, Kim JW, Kim KH, Kim CH, Shim BY, Kim HK (2010) A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer. Lung cancer 68(3):446–449. doi:10.1016/j.lungcan.2009.07.002 PubMedCrossRef

Rhee CK, Lee SH, Kim JS, Kim SJ, Kim SC, Kim YK, Kang HH, Yoon HK, Song JS, Moon HS, Kim JW, Kim CH, Shim BY, Kim HK, Sun DS, Kim KH (2011) A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer. Lung cancer 72(1):64–67. doi:10.1016/j.lungcan.2010.07.003 PubMedCrossRef

10.

von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer MC, Depierre A, Carmichael J, Krebs JB, Ross G, Lane SR, Gralla R (1999) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17(2):658–667

11.

Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, Poulin R, Preston AJ, Dane G, Ross G (2007) Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 25(15):2086–2092. doi:10.1200/JCO.2006.08.3998 PubMedCrossRef

12.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216PubMedCrossRef

13.

Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38(1):143–151PubMedCrossRef

14.

Poplin E, Thompson B, Whitacre M, Aisner J (1987) Small cell carcinoma of the lung: influence of age on treatment outcome. Cancer Treat Rep 71(3):291–296PubMed

15.

Ardizzoni A, Favaretto A, Boni L, Baldini E, Castiglioni F, Antonelli P, Pari F, Tibaldi C, Altieri AM, Barbera S, Cacciani G, Raimondi M, Tixi L, Stefani M, Monfardini S, Antilli A, Rosso R, Paccagnella A (2005) Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis—a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study. J Clin Oncol 23(3):569–575. doi:10.1200/JCO.2005.11.140 PubMedCrossRef

16.

Pallis AG, Shepherd FA, Lacombe D, Gridelli C (2010) Treatment of small-cell lung cancer in elderly patients. Cancer 116(5):1192–1200. doi:10.1002/cncr.24833 PubMedCrossRef

17.

Gridelli C, De Vivo R, Monfardini S (2002) Management of small-cell lung cancer in the elderly. Crit Rev Oncol Hematol 41(1):79–88PubMedCrossRef

18.

Langer CJ, Manola J, Bernardo P, Kugler JW, Bonomi P, Cella D, Johnson DH (2002) Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94(3):173–181PubMedCrossRef

19.

Findlay MP, Griffin AM, Raghavan D, McDonald KE, Coates AS, Duval PJ, Gianoutsos P (1991) Retrospective review of chemotherapy for small cell lung cancer in the elderly: does the end justify the means? Eur J Cancer 27(12):1597–1601PubMedCrossRef

20.

Yoshimura A, Noro R, Miyanaga A, Mizutani H, Kosaihira S, Minegishi Y, Seike M, Hino M, Ando M, Nomura K, Okano T, Kobayashi K, Gemma A, East Japan Chesters G (2012) Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer. Anticancer Res 32(10):4473–4478PubMed

21.

Neubauer M, Schwartz J, Caracandas J, Conkling P, Ilegbodu D, Tuttle T, Asmar L (2004) Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive small-cell lung cancer with Eastern Cooperative Oncology Group Performance Status of 2, or age > or = 70 years. J Clin Oncol 22(10):1872–1877. doi:10.1200/JCO.2004.11.023 PubMedCrossRef

22.

Westeel V, Murray N, Gelmon K, Shah A, Sheehan F, McKenzie M, Wong F, Morris J, Grafton C, Tsang V, Goddard K, Murphy K, Parsons C, Amy R, Page R (1998) New combination of the old drugs for elderly patients with small-cell lung cancer: a phase II study of the PAVE regimen. J Clin Oncol 16(5):1940–1947PubMed

23.

Murray N, Grafton C, Shah A, Gelmon K, Kostashuk E, Brown E, Coppin C, Coldman A, Page R (1998) Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer. J Clin Oncol 16(10):3323–3328PubMed

24.

Okamoto H, Watanabe K, Nishiwaki Y, Mori K, Kurita Y, Hayashi I, Masutani M, Nakata K, Tsuchiya S, Isobe H, Saijo N (1999) Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol 17(11):3540–3545PubMed

25.

Hainsworth JD, Carrell D, Drengler RL, Scroggin C Jr, Greco FA (2004) Weekly combination chemotherapy with docetaxel and gemcitabine as first-line treatment for elderly patients and patients with poor performance status who have extensive-stage small cell lung carcinoma: a Minnie Pearl Cancer Research Network phase II trial. Cancer 100(11):2437–2441. doi:10.1002/cncr.20281 PubMedCrossRef

26.

Bonn O, Schmidt-Wolf G, Risse F, Glasmacher A, Kleinschmidt R, Schmidt-Wolf IG (2005) Vindesine and etoposide: a practical and well-tolerated therapy for elderly patients or patients in reduced clinical condition with extensive-stage small-cell lung cancer (SCLC). Med Sci Monit 11(2):PI19–PI21

27.

Schiller JH, Kim K, Hutson P, DeVore R, Glick J, Stewart J, Johnson D (1996) Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 14(8):2345–2352PubMed

28.

Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, Giaccone G, Schaefer B, Wanders J, Verweij J (1997) Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 15(5):2090–2096PubMed

29.

Negoro S, Fukuoka M, Niitani H, Suzuki A, Nakabayashi T, Kimura M, Motomiya M, Kurita Y, Hasegawa K, Kuriyama T, et al (1991) [A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group]. Gan To Kagaku Ryoho 18(6):1013–1019

30.

Cascinu S, Del Ferro E, Ligi M, Graziano F, Catalano G (1997) The clinical impact of teniposide in the treatment of elderly patients with small-cell lung cancer. Am J Clin Oncol 20(5):477–478PubMedCrossRef

31.

Tummarello D, Isidori P, Pasini F, Cetto G, Cellerino R (1992) Teniposide as single drug therapy for elderly patients affected by small cell lung cancer. Eur J Cancer 28A(6–7):1081–1084PubMedCrossRef

32.

Cerny T, Pedrazzini A, Joss RA, Brunner KW (1988) Unexpected high toxicity in a phase II study of teniposide (VM-26) in elderly patients with untreated small cell lung cancer (SCLC). Eur J Cancer Clin Oncol 24(11):1791–1794PubMedCrossRef

33.

Quoix EA, Giaccone G, Jassem J, Karnicka H, Wiatr E, Cortes-Funes H, Roozendaal KJ, Kirkpatrick A, Evrard D, van Zandwijk N (1992) Epirubicin in previously untreated patients with small cell lung cancer: a phase II study by the EORTC Lung Cancer Cooperative Group. Eur J Cancer 28A(10):1667–1670PubMedCrossRef

34.

Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M (1997) Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15(1):251–260PubMed

35.

Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352(9138):1413–1418. doi:10.1016/S0140-6736(98)02309-5 PubMedCrossRef

36.

Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C (1998) Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352(9138):1407–1412. doi:10.1016/S0140-6736(98)03085-2 PubMedCrossRef

Title: A multicenter phase II study of belotecan, a new camptothecin analogue, in elderly patients with previously untreated, extensive-stage small cell lung cancer
Authors: Chang Dong Yeo
Sang Haak Lee
Ju Sang Kim
Seung Joon Kim
Seok Chan Kim
Young Kyoon Kim
Hyeon Hui Kang
Hyung Kyu Yoon
Jeong Sup Song
Hwa Sik Moon
Jin Woo Kim
Kwan Hyoung Kim
Byoung Yong Shim
Chi Hong Kim
Publication date: 01-10-2013
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 4/2013
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-013-2256-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2013

Receptor tyrosine kinase alterations and therapeutic opportunities in squamous cell carcinoma of the lung

Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma

Clinical evaluation of targeted arterial perfusion of verapamil and chemotherapeutic drugs in interventional therapy of advanced lung cancer

Inhibition of sorcin reverses multidrug resistance of K562/A02 cells and MCF-7/A02 cells via regulating apoptosis-related proteins

Treatment results and prognostic factors for advanced squamous cell carcinoma of the larynx treated with concurrent chemoradiotherapy

Identification of two novel inhibitors of mTOR signaling pathway based on high content screening

Keynote webinar | Spotlight on antibody–drug conjugates in cancer